We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

EKF Ekf Diagnostics Holdings Plc

1.00 (3.85%)
29 Sep 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.

Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  1.00 3.85% 27.00 115,505 16:35:13
Bid Price Offer Price High Price Low Price Open Price
26.10 27.00 26.60 26.00 26.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Med, Dental, Hosp Eq-whsl 66.64 -10.10 -2.20 - 122.83
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:13 UT 11,062 27.00 GBX

Ekf Diagnostics (EKF) Latest News

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics (EKF) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Ekf Diagnostics (EKF) Top Chat Posts

Top Posts
Posted at 30/8/2023 18:05 by wan
Yes, it perhaps does well to not raise expectations too high.

But it's perhaps also worth recalling that EKF's established Life Science division recorded 60% year-on-year growth in 2022, and EKF's enhanced fermentation offering has already received high demand, with the Executive Chair stating that Life Sciences fermentation investment is "offering the potential for significant revenue growth beyond current conservative guidance". Time will tell!

From the AR - Our Life Sciences division grew by 60% to £3.2m (2021: £2.0m). We believe that this is a highly-scalable business unit, where we can take advantage of a demand-driven opportunity to produce research and diagnostic enzymes in the molecular and clinical chemistry markets, and in industrial and agricultural enzymes settings as well as food grade fermentation digestive proteins. Our production expansion is for customers that we have established relationships with, and who are well advanced in the process of transferring to our enzyme contract manufacturing services delivered from our two US sites in Indiana.

We were previously guided that a range of large companies are set to utilise EKF's fermentation capabilities and increased capacity. For example EKF are involved in producing biological enzymes for use in agriculture, which is an area that I have previously investigated and researched (not EKF), but it is something that I have recently taken a 'specific' and closer look at.

In the meantime, I am particularly keen to learn who will fill the role of CEO.
Posted at 16/8/2023 14:36 by wan
EKF is showcasing its products and services at Medlab Asia 2023, held in Bangkok, Thailand, between 16-18 August.

EKF delivers diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care testing and life sciences applications.

EKF leads the way with cutting-edge point-of-care diagnostic solutions that empower healthcare professionals and patients with rapid, accurate, and accessible testing capabilities and results. Our technologies enable informed decision-making, timely interventions, and improved patient outcomes at the point-of-care.

EKF is at the forefront of supporting life sciences applications and research through innovative biotechnology solutions. Our comprehensive portfolio equips researchers, scientists, and clinicians with powerful tools for accurate and reliable delivery and results, driving breakthrough discoveries and advancements in healthcare and medical understanding.

Explore the upcoming breakthroughs in point-of-care, life sciences, and clinical chemistry. Don't miss the chance to experience our revolutionary EKF Link platform -

Visit our team at booth #H6.B30 to find out more!
Posted at 24/7/2023 09:42 by wan
Food for thought:

Back in March, and without the upside from the new fermentation facility, EKF's 2023 revenue was forecast at £57m (of which around £40m is recurring revenue) with EBITDA forecast at £14.1m, which according to my math, and based on EKF's current valuation, results in an EBITDA multiple of 8.7 X

Although last week EKF closed 18.40% above the 52 week low of 23.10p set on May 18, 2023 (source FT.com), the shares have recently pulled back to a similar level in share price terms to that in March 2023, when (according to the Executive Chairman) EKF was being valued at 7 x 2024 EBITDA. Most would put that pullback down to the recent uncertainty surrounding the moves and change at board level.

Assuming that the performance and prospects for the business have not materially deteriorated, if that type of undervaluation/underappreciation persists beyond the anticipated results, and given how the US rates and values businesses compared to the UK, then perhaps a US listing might become a nearer term reality. In the US, companies such as EKF that can forecast and deliver profitable growth, has a high level of recurring revenue, pays a dividend, and has no long term debt, would likely be rated far more highly.

Although the link further below does not include microcaps etc, it provides at least some guidance and highlights the gaping difference between the US and the UK in terms of equity valuations.

In terms of industry/sector, EKF spans across Life Sciences Tools and Services, and Health Care Equipment and Supplies. According to Interpath, both of these industry/sectors are rated in the top 10 in terms of EBITDA multiples in the US, at 18.62 X and 17.56 X respectively, giving an average of 18X. In the UK, Health Care is pegged at 7.33 X and appears to be based only on pharmaceuticals (again highlighting an important difference).

Readers can apply what they think is an appropriate multiple and do the maths using EBITDA of £14.1m for 2023 and circa £18m for 2024 in order to arrive at a notional/potential market capitalisation, and the same with regard to a notional/potential share price (in round figures, EKF has 455m shares in issue).

Although the following does not include microcaps or AIM stocks etc, it provides at least some guidance as to the gaping difference from a sophisticated comparison of sector and industry on how UK and US companies are valued, and highlights the material difference between the US and the UK in terms of valuation multiples for industry/sectors -

Valuation Multiples by Industry 24 May 2023

In any regard, the difference is notable, and no wonder then that the UK is fertile hunting ground for US companies! And perhaps highlighting the apparent threats to, or the assumption that the UK holds a leading position as a global and vibrant financial centre (although reforms are afoot aimed at making London a more attractive place to list).

In the meantime, the Trading Update may well provide some guidance as to how far out, or not, the market is in terms of valuing EKF's persistent, reliable recurring revenues, and its significant growth prospects.
Posted at 18/5/2023 08:16 by wan
As promised, a few snippets of information from quickly taken notes during the AGM (albeit that audible transmission during the meeting was not always perfect). I may add more detail if I have missed anything amongst my scrawled notes! -

Russia: Accessing the dividend being held in Russia is still problematic. However, EKF are still selling diagnostics to Russia (essential medical diagnostics are allowed), but at significantly increased prices with upfront payment, resulting in the amount of cash under restriction not growing. EKF are routinely taking legal advice as the situation re sanctions is constantly changing.

Veterinary lactate testing is currently a small percentage of sales, but there is real utility and demand, and therefore sales will likely increase over time. EKF now has in-house veterinary expertise/sales capabilities to address the opportunity (previously not in place).

Artificial intelligence (AI) is being used to develop the enzymes that EKF manufacture, and includes CRISPR 9 enzyme manufacturing for use in molecular diagnostics. For context, it is considered by some experts that CRISPR-based diagnostics could reshape the field of point-of-care molecular diagnostics (Julian described a CRISPR based diagnostic as incredible (or something like that). Readers may recall that EKF highlighted in a recent presentation that molecular enzymes will be manufactured for both third party OEM, and EKF brand.

AI optimises the fermentation process ultimately unlocking even more potential from precision fermentation and creating refined, differentiated products across a range of markets, including pharmaceutical, diagnostics, food, and food production.

A range of large companies are set to utilise in EKF's fermentation capabilities and capacity, for example EKF are involved in producing biological enzymes for use in agriculture.

EKF's Elkhart fermentation facility will serve as an important R&D hub ahead of advancing projects to scaled-up production.

Julian Baines, in describing the level of demand for EKF's enhanced fermentation offering, said that 'he had never seen this level of enquiries in my career', and further stated that 2024 is looking to be very successful with the investment in fermentation capacity and capabilities offering shareholders the biggest growth opportunity in 10 years.

The COVID pandemic has changed our relationship and familiarity with at-home testing. Point of care testing in the UK got a mention during the AGM, in terms of the potential from testing at home and at pharmacies. See today's news below from MyHealthChecked (an EKF customer).
Posted at 27/3/2023 15:02 by wan
As I stated previously (in post 3021), I appreciate that a reset was inevitable post the Trading Update in February this year, but despite considerable growth in the established core businesses compared to pre-pandemic levels, in share price terms EKF is back to pre-pandemic levels when both the FY revenue in 2019 (£44.9m) and the growth prospects for the core business were materially less than they are today.

And whilst I appreciate the frustration and the fact that the market can over-react in both directions, suggestions that the shares could hit 16p and even 10p appear delusional/scaremongering (and perhaps wishful thinking by some). Time will tell!

Whilst ADL has not been a successful investment (of EKF's time and money), it was always non-core, but some have interpreted that the cash EKF has generated to date has been blown. However, given the planned investments made during the year, including the significant capital expenditure to increase EKF's enzyme fermentation capacity in the US, that assumption, at this stage at least, appears 'wildly' overstated!

The current share price weakness is increasingly looking too harsh, and recently resulted in EKF's broker describing its shares as being in "deep value territory and offer a strong buying opportunity". However, I understand and respect that the current uncertainty will hold the shares back until we get further clarity and vision, which is likely to come tomorrow. In short, I don't think investors will have to wait too long for a re-rating of EKF's shares, as meaningful contract news will also surely emerge.

Staying with meaningful contracts, recall that EKF signed an exclusive, multi-million dollar agreement with Oragenics, Inc., a Florida-based biopharmaceutical company, for the manufacturing of Oragenics' lantibiotic bulk drug substances in the United States. Under the collaboration agreement, EKF Diagnostics will manufacture compounds intended for preclinical and early-stage clinical trials, which along with other projects were paused as a result of COVID-19. I noted recently that Oragenics Lantibiotic project has made further progress -

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

March 14, 2023
Potentially Addresses Life-Threatening Antibiotic-Resistant Infections

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings from third party laboratory testing of several compounds in Oragenics’ lantibiotics platform to combat multiple pathogens despite the resistance of those pathogens to standard-of-care antibiotics. Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.

Kim Murphy, President and Chief Executive Officer of Oragenics, commented, “We previously reported that cross-resistance does not appear to emerge with our novel class of antibiotics because of their unique mechanism of action. We are encouraged by the outcomes of our recent collaboration with Linnaeus, which verify that life-threatening pathogens that are resistant to drugs of last resort – including vancomycin and daptomycin – remain sensitive to several of our lantibiotic compounds. This is another significant step in efforts to identify a new lead compound to advance into the clinic toward the development of novel therapies to fight infectious diseases."

Thus, I remain patiently invested and having also added to my position at recent lows (prior to the recent broker note).
Posted at 18/2/2023 06:35 by wan
I was out of the office yesterday afternoon/evening.

I finished typing up the following on Thursday when the shares were trading at around 26p. My intention was to post it today (or Monday subject to finishing off some tweaks and research), but in my view and even with yesterdays price action, EKF shares appear very cheap -

I appreciate that a reset was inevitable post the Trading Update, but despite considerable growth in the established core businesses compared to pre-pandemic levels, in share price terms EKF is back to a pre-pandemic levels when both the FY revenue in 2019 (£44.9m) and the growth prospects for the core business were materially less than they are today. On the face of what is known, this appears harsh, but others will say the market is correct, but most will also know that the market can over-react in both directions.

Obviously the main issue is the uncertainty as to what exactly the FY Results and the forecast for 2023 and beyond will contain, but the market is certainly factoring in quite a lot of disappointment!

In my view, it's quite clear that the delay in the transition to non-COVID contract manufacturing, and perhaps to a large degree, is intrinsically linked to the delayed installation and validation of the new fermentation enzyme facility. Put another way, the use of enzymes in molecular and forensic test kits is thus also delayed. There has also been some customer enhancements/changes to factor in (see my Life Sciences comment further below).

The delay in the transition to non-COVID testing at ADL, may, at least in part, also be linked to the new enzyme facility e.g. In next-generation sequencing (NGS) custom-formulating enzymes and master mixes are used in the NGS workflow. And ADL has been building/installing NGS testing capabilities. Other non-COVID testing now appears to be increasing though.

These factors are almost certainly why EKF stated that "Completion of the capacity expansion at the enzyme fermentation facility in South Bend, Indiana, remains the main short-term priority for the Group." Put another way, completion of the fermentation facility is likely to have a large impact in more ways than one!

EKF stated the following in their Trading Update -

3. Contract Manufacturing - Reducing cost base as operations shift into non-COVID-revenues

In the US, the Company's non-COVID Contract Manufacturing services continues to develop, focused on working with innovative companies in the areas of genomics and forensics to support their growth ambitions. In 2023 this division's focus will be on expanding this service line utilising the Company's asset base in the US and Germany.

Again I would flag the use of enzymes being used in the areas of genomics and forensics. In NGS sample and library preparation, you probably use enzymes at almost every critical step (source: Cytiva).

Staying with enzymes: what caught my attention some time ago, was the notable increase in the indicated fermentation capacity between the Growth Strategy Presentation (reported in June 2021) - comprising 300L 1,500L 3,000L 14,700L units, and at the Half-year Report (reported in September 2022) - comprising 65L, 300L, 1,500L, 3,000L, 10,000L and 14,500L units. So, the capacity increase may also be part of the indicated cost increase i.e. capacity increase and the technology/process enhancements. Importantly, the delays have not affected relationships with EKF's key customers that are looking to utilise the enzyme capacity and expertise, implying that the enhanced customer requirements played their part.

Given the apparent strong level of interest from a range of corporates, it will thus be interesting to see where the installed fermentation capacity eventually lands, and where the 2024 revenue forecast is pegged for the new fermentation facility, which previously had the aim of delivering $20m in revenues by 2024. Although growth in 2023 has been affected, it is notable that EKF still expect the full positive impact of the increased enzyme capacity to be realised in 2024, none of which was on the radar in 2019 (cue my comment above regarding the current share price reflecting prospects and revenue from 2019).

There are, from what I can tell, some relatively large players aligning with some of EKF's existing and new offerings, including contract manufacturing and the new enzyme project. Implying that EKF has the potential to become a 'materially' larger company in terms of revenue and market cap. Clearly though, 2023 looks set to be a challenge for the management (and investors), but patience could be well rewarded.

I am thus sticking with my view that the Growth Plan has suffered a setback and has not been blown completely off course, with the main ingredients and direction of travel still intact, and maybe even enhanced.

As always, please conduct you own research when making investment decisions as I, or the threads contributors, could be either wrong or inaccurate.
Posted at 01/11/2022 15:05 by wan
Heads-up via Walbrook PR -

EKF to showcase POCT connectivity solutions at MEDICA 2022
1st November 2022

Powerful digital connectivity products and contract manufacturing capabilities in Hall 3 at Stand B69

EKF Diagnostics, a global diagnostics company, will be introducing its latest product developments and offerings at MEDICA 2022, Düsseldorf, Germany, 14-17 November. Highlighted at the event will be its newly introduced point-of-care testing (POCT) connectivity solutions, including the enhanced DiaSpect Tm hand-held hemoglobin analyzer and the new EKF Link digital connectivity software. In addition to its POCT products, EKF will also highlight its growing contract manufacturing services to the healthcare industry.

In Hall 3 at Stand B69, the EKF team will be available to demonstrate how its new state-of-the-art EKF Link middleware enables healthcare providers to readily manage their POC analyzers and all generated data via one centralized platform. An intuitive, open solution, EKF Link can be interfaced to most vendor’s POC analyzers, in addition to EKF’s own portfolio. This facilitates real-time remote management and secure transfer of data, including patient test results, QC results, operator management and analyzer configuration within a range of healthcare settings.

Adding to the ever-growing list of POC analyzers that are compatible with EKF Link, the enhanced DiaSpect Tm hemoglobin analyzer now offers calculated hematocrit values, and its rapid test results can be securely sent to centralized Laboratory Information Systems (LIS) or Patient Information Systems (PIS). The palm-sized analyzer’s new digital connectivity capabilities enabled by EKF Link also allows authorized users to easily access its near-patient results through a web browser, whatever their location, supporting seamless patient care.

EKF will also be highlighting its global contract manufacturing capabilities covering configuration of product, sourcing materials, providing state-of-the-art bulk formulation and dispensing facilities, through to services such as kitting, labelling and packaging. With extensive facilities in the USA, UK and Germany, EKF has a proven track record of developing and manufacturing quality products for a range of markets, industries, and businesses - from start-ups to industry leaders – across the globe.

MEDICA 2022 brings together industry leaders, global healthtech professionals, start-ups and experienced high-tech products in the medical technology arena.

Discussing how EKF’s contract manufacturing team has supported his start-up health technology company, Elliot Quigley, Project Manager, Proton Dx, said: “EKF Diagnostics has been instrumental in our development as a company. They worked above and beyond their remit to ensure the successful completion of our pivotal milestones. They worked closely with our team to provide solutions and guidance navigating the tricky start-up landscape, whilst providing top-tier products.”

Mike Salter, CEO, EKF Diagnostics, said: “We look forward to welcoming visitors to our stand at MEDICA where our team of product and contract manufacturing specialists will be on hand to discuss our broad range of medical diagnostics products and manufacturing services. We are particularly excited to be able to demonstrate our enhanced capabilities in POCT connectivity which provides hospitals, laboratories and clinicians with the ability to manage and evaluate their patient and user data easily and securely.”
Posted at 04/8/2022 20:31 by james188

I think that you ask some legitimate questions in relation to the various companies that have been spun out of the Mount Sinai/EKF relationship. I should say that I am a reasonably long term investor in EKF.

The share price performance of the three companies that you mention has obviously been disappointing (ditto the EKF share price), but they are all cash hungry early stage entities and I think that it is too early to make a definitive judgement.

I do not think that EKF is large enough to financially further support these investments. They will all inevitably need to raise further funds and so there is a significant risk of dilution as EKF will struggle - and much more so its shareholders - to participate. EKF has much better use for its cash in growing the core business (which is doing well). It is worth noting that EKF has not spun out a further company for some time and rejected a deal that was put forward last year. That may signify a change in strategy under the new management team.
Posted at 03/8/2022 11:51 by rivaldo
Techinvest have published their new issue, so it should be OK to copy their Buy update on EKF from the July issue:

"EKF Diagnostics

EKF has announced the intention to distribute shares in its investment, Verici Dx, to the company’s shareholders who will receive one investment share for every 50 ordinary shares held in EKF. In order to maintain an orderly market in Verici’s shares following the distribution, the shares will be held in trust for shareholders for a period of a year. During the lock-up period, EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Verici investment shares.

Verici is a developer of advanced clinical diagnostics for organ transplant. The company is one of three business that have emerged so far from EKF’s preferred partnership agreement to develop healthcare technologies alongside Mount Sinai Health System. The other businesses are Renalytix, which is currently trading on AIM and Nasdaq, and Trellus Health. Both Trellus and Verici are listed on AIM. EKF reported owning around 5.7% of Verici’s shares at the time of the company’s final results announcement in March. The partnership with Mount Sinai is proving fruitful and represents an asset that investors may be overlooking when valuing shares in EKF.

We feel that the company’s core business alone is somewhat undervalued by the current share price. Stripping out net cash of 4.6p per share, the shares trade on a prospective P/E of 14.1 for the current year, falling to 11.4 for fiscal 2023. Add in the projected value of the business investments in the Mount Sinai partnership and the stock looks excessively neglected. Buy."
Posted at 01/7/2022 14:23 by wan
'On plan' news -

Industry News: EKF to highlight specific glycemic control marker at AACC 2022
EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637
30 Jun 2022

EKF Diagnostics, a global in vitro diagnostics company, will be at the 2022 AACC Clinical Lab Expo, Chicago IL, July 26-28, exhibiting its range of laboratory and point-of-care diagnostics products on Booth #3637. This includes the FDA cleared Lucica® Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the U.S. by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate term monitoring of glycemic control in diabetes patients.

Lucica® Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analyzers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions and the results are expressed as a ratio (%), minimizing differences in albumin concentrations between patients. Lucica® is also standardized to an established reference material.

“The Lucica® Glycated Albumin-L is sold exclusively by EKF Diagnostics in the U.S. and complements our existing diabetes product range, offering its own utility as a specific, intermediate glycemic control marker,” said Shane O’Neill, Global Director of Scientific Affairs, EKF Diagnostics.

Alongside its range of clinical chemistry tests and diagnostics analyzers, also available to view on EKF’s Booth at AACC will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analyzers and associated data on one centralized platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure, and effective POC testing using analyzers in many differing locations.

EKF Link middleware is an open and flexible solution which can be interfaced to all vendors’ POC analyzers, including EKF’s own portfolio, to enable real-time remote management of data, including patient test results, QC results, operator management, and analyzer configuration. The user-friendly software allows POC analyzers to connect to a hospital or laboratory’s IT system, enabling data transfer from the remote analyzers for subsequent processing. This provides hospitals, laboratories, and clinicians with the functionality to manage and evaluate their patient and operator data easily and securely.

EKF’s portfolio of POC diagnostic devices includes Hemo Control and DiaSpect Tm hemoglobin analyzer ranges, as well as Quo-Lab and Quo-Test HbA1c analyzers. All of these can now be digitally connected from anywhere and securely accessed remotely at any time using EKF Link, thereby enhancing their capabilities.

Recall from the EKF Link RNS -

The development and launch of EKF Link has been driven by customer demand and designed in partnership with hospital POC managers to ensure the software meets their specific needs. EKF Link provides the Company with improved competitive positioning for future POC contract tenders and new accounts, and increases the attractiveness of the EKF product portfolio to existing customers against currently available technologies.

Mike Salter, CEO, of EKF Diagnostics said: "As part of our strategy to enhance our POC analyser portfolio and technology offering, we are pleased to announce that we have successfully launched EKF Link enabling practitioners to analyse their patients' results remotely, easily and securely. EKF Link provides our POC diagnostic devices with a connectivity advantage which positions us well for tenders and new accounts. This is particularly true in Europe and North America, where a connectivity solution is commonly a part of the specification. EKF Link has the added benefit that it can be installed wherever it is needed, on a PC or a central server, allowing hospitals and laboratories, technicians and clinicians to access results from various settings, reducing workload whilst increasing the security of handling patient data.

"This new product launch shows our responsiveness to our customer base and increasing demand for data management capabilities. It extends the utility of our installed instrument base and provides EKF with a key advantage for further new business opportunities."
Ekf Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230930 18:46:40